Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Armin Schulz on September 4th, 2024 | 07:30 CEST

Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance

  • Biotechnology
  • Biotech
  • Pharma

Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.

Read

Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST

Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec

  • Biotechnology
  • Biotech
  • Pharma

Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.

Read

Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST

In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac

  • Biotechnology
  • Biotech
  • Pharma

The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.

Read

Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST

BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?

  • Biotechnology
  • Biotech
  • Pharma

On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.

Read

Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST

BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions

  • Biotechnology
  • Pharma
  • Biotech

Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.

Read

Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

  • Biotechnology
  • Biotech
  • Pharma

The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

Read

Commented by Juliane Zielonka on July 5th, 2024 | 07:35 CEST

Vidac Pharma, BioNTech, GSK: Pioneers in medical progress - Who will win the race?

  • Biotechnology
  • Biotech
  • Pharma

With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now?

Read

Commented by André Will-Laudien on July 1st, 2024 | 07:00 CEST

Attention: Biotech stocks! Evotec, Bayer, and BioNTech in the emergency room, but Cardiol Therapeutics shows strength!

  • Biotech
  • hightech
  • Biotechnology
  • Pharma

Anyone looking at the buying frenzy on the NASDAQ is overlooking the fact that the US has long been in the emergency room. With the candidates currently up for election, it is unlikely that the most pressing issues of the day will be dealt with. One has difficulty using the right words in front of the camera, while the other ignores facts and slips into his own world. This election could be disastrous for the world's largest economy, but the financial markets are currently uninterested. Investors should, therefore, continue to separate the wheat from the chaff and act prudently. After the big AI and high-tech wave, biotechs are expected to make a comeback, as US interest rates will drop closer to the election. We present a solid selection for risk-conscious investors.

Read

Commented by Fabian Lorenz on June 25th, 2024 | 07:00 CEST

300%-Opportunity, problems, and the German Chancellor: Bayer, BioNTech, and Cardiol Therapeutics

  • Biotechnology
  • Pharma

Bayer is making positive headlines for a change. Following takeovers in cell and gene therapy, the Company is investing in Berlin and has brought the renowned Charité Hospital on board. Federal Chancellor Olaf Scholz gives the go-ahead for the project. Can the share benefit from this? The sell-off in Cardiol Therapeutics shares after positive study results was a surprise. Analysts are enthusiastic, raising price targets and seeing 300% potential. On the other hand, BioNTech shares are currently not an obvious buy. And now there are also problems with the FDA in the US. This is causing alarm among shareholders and impacting the share.

Read

Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

  • Hydrogen
  • greenhydrogen
  • Biotechnology

Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.

Read